Clinical trials: HIV 1 Infection
Human Immunodeficiency Virus (HIV)
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
The purpose of this study is to evaluate the safety and tolerability of repeat doses of T-cell immunotherapy (SB-728mR-T) following cyclophosphamide conditioning. CCR5 is a major co-receptor for HIV entry into T-cells.
- Trial name
- NCT02225665
- Testing
- SB-728mR-T, Cyclophosphamide
- Where
- 5 sites in United States
- Volunteers
- 8 people
- Sponsor
- Sangamo Therapeutics
HIV Infections
A Phase I/II Dose Escalation Study of Intradermal gp160 to Evaluate Safety, Delayed Type Hypersensitivity (Skin Test) Responses and Immunogenicity in Asymptomatic HIV Seropositive Patients With More Than 400 CD4+ Cells
To determine the safety of intradermal gp160 in HIV seropositive individuals who are asymptomatic and have a relatively intact immune system.
- Trial name
- NCT00000667
- Testing
- gp160 Vaccine (MicroGeneSys)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Intermittent Therapy in HIV-1 Infected Patients With Successful Viral Suppression Under Highly Active Antiretroviral Therapy (HAART)
Although lifelong continuous therapy with HAART remains the standard of care of HIV infection, allowing to achieve undetectable plasma viral RNA, restore CD4 cell count and provide substantial decline in HIV-related morbidity and…
- Trial name
- NCT00122551
- Testing
- Intermittent antiretroviral therapy
- Where
- 2 sites in France
- Volunteers
- 400 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
AIDS/HIV PROBLEM
Study on the Impact of Triptolide Woldifiion on HIV-1 Reservoir In Acute HIV-1 Infection
This study is a prospective trial which will recruit 18 patients in acute HIV-1 infection phase. This study aims to evaluate the effects and side effects of ARV treatment in Chinese patients in acute HIV-1 infection phase, and to…
- Trial name
- NCT02219672
- Testing
- Triplitode, Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Peking Union Medical College
HIV Infection, Hemophilia A
Efficacy and Safety of MK-0518 in Treatment-Experienced HIV-1 Infected Adult Patients With Hemophilia
This is an randomized, double-blind, placebo-controlled study to assess the safety, tolerability and efficacy of MK-0518 compared to placebo when combined with other antiretroviral drugs, in treatment-experienced HIV-infected…
- Trial name
- NCT00797381
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai Public Health Clinical Center
HIV Infections
Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load
Switching from enfuvirtide to raltegravir in the treatment of HIV-infected patients who sustain viral suppression with a combination therapy including enfuvirtide (or : with an enfuvirtide-based combination therapy)
- Trial name
- EASIER (NCT00454337)
- Testing
- FTC/TDF + EFV or LPV/R +T20, FTC/TDF + EFV or LPV/R
- Where
- France
- Volunteers
- 170 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV Infections
Inflammation, NK Cells, Antisense Protein and Exosomes, and Correlation With Immune Response During HIV Infection
More than 90% of HIV-infected patients on antiretroviral therapy have an undetectable viral load. However, approximately 15% of these individuals do not sufficiently restore their TCD4 lymphocytes and have an unfavorable CD4/CD8…
- Trial name
- INKASE (NCT05243381)
- Testing
- 20 ml blood test
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Montpellier
Acquired Immunodeficiency Syndrome, HIV Infections
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
This study is to characterize the effect of cobicistat-based regimens on parameters of renal function in participants with HIV infection and who have mild to moderate renal impairment, and to assess the safety and tolerability of…
- Trial name
- NCT01363011
- Testing
- E/C/F/TDF, COBI, ATV
- Where
- 51 sites in United States, Australia and 7 more
- Volunteers
- 106 people
- Sponsor
- Gilead Sciences
HIV Infections, Hepatitis C
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
HIV and hepatitis C virus (HCV) infection are diseases that share the same risk factors and routes of transmission. For this reason, many people infected with HIV are also infected with HCV.
- Trial name
- C_ASCENT (NCT02194998)
- Testing
- Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), Dasabuvir (DSV), Ribavirin (RBV)
- Where
- 16 sites in United States, Puerto Rico
- Volunteers
- 46 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
Use of Combined Antiretroviral Therapy to Determine Sites of Persistent HIV Infection
This study will try to define how and where HIV infection persists in the body by determining: 1) if there are cells where HIV can live for long periods of time without being seen and destroyed by the immune system; 2) if there…
- Trial name
- NCT00001644
- Testing
- Indinavir, Zidovudine, Lamivudine
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
PREventing Progression of Adipose Tissue Redistribution
The main objective of the study is to assess changes in fat distribution over 48 weeks of treatment in patients who currently successfully use zidovudine (AZT) and lamivudine (3TC) as part of their regimen and who will either…
- Trial name
- NCT00389194
- Testing
- continuing AZT+3TC or switching AZT+3TC to TDF+ FTC
- Where
- Netherlands
- Volunteers
- 120 people
- Sponsor
- International Antiviral Therapy Evaluation Center
HIV-1-infection
ANCHORS Study: UH2 Project
According to the National HIV/AIDS Strategy, men who have sex with men (MSM), young adults, Black and Latino men and people in the Southern U.S.
- Trial name
- ANCHORS (NCT03360422)
- Testing
- Survey, Focus Group, Usability study
- Where
- United States
- Volunteers
- 673 people, healthy volunteers welcome
- Sponsor
- University of Florida
HIV Infections
Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine
The purpose of this study is to evaluate the safety and immune response to an HIV clade C vaccine and to an MF59- or alum-adjuvanted clade C Env protein in healthy, HIV-uninfected adults.
- Trial name
- HVTN107 (NCT03284710)
- Testing
- ALVAC-HIV (vCP2438), Bivalent Subtype C gp120/MF59, Bivalent Subtype C gp120 admixed with Al(OH)3 Suspension
- Where
- 6 sites in Mozambique, South Africa and 1 more
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
The Effects of Anti-HIV Drugs on the HIV Virus in HIV-Infected Patients
The purpose of this study is to examine the HIV virus in the blood and lymphoid tissues of patients taking anti-HIV medications. HIV infection is closely linked to the growth of the HIV virus in the body.
- Trial name
- NCT00006442
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1-infection
Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation in HIV Infected Adults
UB-421 subcutaneous formulation (UB-421 SC) is developed to provide HIV infected patients a more convenient drug delivery method.
- Trial name
- NCT04620291
- Testing
- UB-421 SC
- Volunteers
- 18 people
- Sponsor
- United BioPharma
Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection. The goals of this study are to learn: If taking MK-8527 once a month works to prevent HIV-1 infection as well as or…
- Trial name
- NCT07044297
- Testing
- MK-8527, FTC/TDF
- Where
- 81 sites in United States, Argentina and 14 more
- Volunteers
- 4,390 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV-1 and HSV-2 Coinfection, HIV Infections
Usage of Acyclovir for Suppression of HIV-1 and HSV-2 Coinfected Persons in Cameroon
The study proposed that both clinical and subclinical HSV reactivation is associated with increased HIV shedding from mucosal surfaces, which may increase the infectiousness of HIV-1/HSV-2 coinfected persons.
- Trial name
- NCT00209313
- Testing
- Acyclovir
- Where
- Cameroon
- Volunteers
- 40 people
- Sponsor
- Fred Hutchinson Cancer Center
Methamphetamine-dependence, HIV-1-infection
Contingency Management for PrEP Adherence and/or Methamphetamine Use
Use of crystal methamphetamine (MA) leads to changes in sexual risk behavior, adherence to HIV prevention tools, immune response to infection, and tissue inflammation that collectively increase risk for HIV transmission among…
- Trial name
- C-MAX (NCT04563962)
- Testing
- Contingency Management-ART, Contingency Management-Methamphetamine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
HIV, Inflammation
CC-11050 in Human Immunodeficiency Virus-1-Infected Adults With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE)
Background: When there is a threat to the body, the immune system triggers inflammation. Too much inflammation can damage the body or cause painful symptoms.
- Trial name
- NCT02652546
- Testing
- Assess Safety, Effect of drug on viral load, Effect of drug on T-cell count
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults
This a phase 1 first-in-human clinical trial to evaluate the safety, tolerability, and immunogenicity of BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in up to 60 healthy adult HIV-uninfected volunteers.
- Trial name
- NCT03699241
- Testing
- BG505 SOSIP.664 gp140, adjuvanted
- Where
- 3 sites in United States, Kenya
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative